Pilz, Georg
Wipfler, Peter
Otto, Ferdinand
Hitzl, Wolfgang
Afazel, Shahrzad
Haschke-Becher, Elisabeth
Trinka, Eugen
Harrer, Andrea
Article History
Received: 18 September 2018
Accepted: 10 January 2019
First Online: 19 January 2019
Ethics approval and consent to participate
: This retrospective study was approved by the local ethics committee of Salzburg (415-E/2218/5-2017).
: not applicable
: GP, WH, SA, EHB, and AH declare that they have no competing interests. PW received a speaker’s honoraria/research funding/travel support from Novartis, Biogen, Merck Serono, Bayer, Teva, and Genzyme. FO received travel support from Novartis, Biogen, Merck Serono, Bayer, Teva, and Genzyme. ET reports personal fees from Eisai, personal fees from Everpharma, grants and personal fees from Biogen Idec, personal fees from Medtronics, personal fees from Bial, personal fees from Newbridge, grants and personal fees from UCB Pharma and Eisai, personal fees from GL Pharma, personal fees from GlaxoSmithKline, personal fees from Boehringer, personal fees from Viropharma, from Actavis, grants from Red Bull, grants from Merck, grants from European Union, grants from FWF Österreichischer Fond zur Wissenschaftsförderung, grants from Bundesministerium für Wissenschaft und Forschung, and grants from the Jubiläumsfond der Österreichischen Nationalbank, outside the submitted work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.